Subsequently, urea-based and phosphonic acid-based PSMA ligands have been investigated, developed, and continuously improved for use in the diagnosis and treatment of prostate cancer through PSMA targeting [57,58,59]. The gene discussed is FOLH1; the disease is prostate carcinoma.